Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042

Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042 - Trial in Progress

Description & Faculty

New trial in progress enrollment information for advanced and recurrent endometrial cancer - Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042

	Robert Coleman, MD, FACOG, FACS Chief Medical Officer Vaniam Group USA
	Floor Backes, MD Moderator Director of Clinical Research and Fellowship Director for the Division of Gynecologic Oncology The Ohio State University Wexner Medical Center James Comprehensive Cancer Center USA

Supported in part by

Summary


Availability:	On-Demand


Cost:	FREE

Create Account

Recommended

An Evolving Frontier: Endometrial Cancer Treatment

FREE

Immunotherapy and its impact on overall survival in patients with recurrent endometrial cancer

FREE

Mismatch repair endometrial cancer, what to do at first recurrence and beyond?

FREE

Emerging data in platinum resistance advanced ovarian cancer

FREE

Radical Hysterectomy - Surgical Film Festival

$0.00 - $50.00

International Gynecologic Cancer Society and International Journal of Gynecological Cancer Evidence-Based Medicine for Gynecological Oncology Curriculum (EBM on the GO)

FREE

Emerging data in platinum resistance advanced ovarian cancer - Webinar

FREE

Encouraging Results Seen in Patients with Heavily Pre-Treated Low-Grade Serous Ovarian

FREE

Multidisciplinary Approach to Treating Advanced Endometrial Cancer

FREE

Multidisciplinary Approach to Treating Advanced Endometrial Cancer - Webinar

FREE